SNDX vs. NAMS, ARDX, EVO, KROS, KURA, HRMY, EWTX, GPCR, PTGX, and GLPG
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include NewAmsterdam Pharma (NAMS), Ardelyx (ARDX), Evotec (EVO), Keros Therapeutics (KROS), Kura Oncology (KURA), Harmony Biosciences (HRMY), Edgewise Therapeutics (EWTX), Structure Therapeutics (GPCR), Protagonist Therapeutics (PTGX), and Galapagos (GLPG). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
Syndax Pharmaceuticals received 356 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 64.79% of users gave Syndax Pharmaceuticals an outperform vote.
NewAmsterdam Pharma has lower revenue, but higher earnings than Syndax Pharmaceuticals.
Syndax Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.
Syndax Pharmaceuticals presently has a consensus price target of $34.42, suggesting a potential upside of 71.40%. NewAmsterdam Pharma has a consensus price target of $33.25, suggesting a potential upside of 71.30%. Given Syndax Pharmaceuticals' higher probable upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than NewAmsterdam Pharma.
NewAmsterdam Pharma's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.
In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Syndax Pharmaceuticals and 3 mentions for NewAmsterdam Pharma. Syndax Pharmaceuticals' average media sentiment score of 1.11 beat NewAmsterdam Pharma's score of 0.72 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
NewAmsterdam Pharma beats Syndax Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
